TECTONIC THERAPEUTIC INC (TECX) Stock Price & Overview
NASDAQ:TECX • US8789721086
Current stock price
The current stock price of TECX is 30.72 USD. Today TECX is down by -1.19%. In the past month the price decreased by -9.96%. In the past year, price increased by 90.1%.
TECX Key Statistics
- Market Cap
- 576.922M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -4.05
- Dividend Yield
- N/A
TECX Stock Performance
TECX Stock Chart
TECX Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to TECX. When comparing the yearly performance of all stocks, TECX is one of the better performing stocks in the market, outperforming 92.88% of all stocks.
TECX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to TECX. TECX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
TECX Earnings
TECX Forecast & Estimates
15 analysts have analysed TECX and the average price target is 79.82 USD. This implies a price increase of 159.81% is expected in the next year compared to the current price of 30.72.
TECX Groups
Sector & Classification
TECX Financial Highlights
Over the last trailing twelve months TECX reported a non-GAAP Earnings per Share(EPS) of -4.05. The EPS increased by 50.49% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -28.41% | ||
| ROE | -29.5% | ||
| Debt/Equity | 0 |
TECX Ownership
TECX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.02 | 367.796B | ||
| AMGN | AMGEN INC | 15.37 | 189.224B | ||
| GILD | GILEAD SCIENCES INC | 15.72 | 172.517B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.4 | 110.97B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.97 | 79.171B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 47.19 | 42.718B | ||
| INSM | INSMED INC | N/A | 33.416B | ||
| NTRA | NATERA INC | N/A | 27.358B | ||
| BIIB | BIOGEN INC | 10.73 | 25.385B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.56 | 25.059B | ||
| MRNA | MODERNA INC | N/A | 20.21B | ||
| INCY | INCYTE CORP | 12.41 | 19.119B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.11B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About TECX
Company Profile
Tectonic Therapeutic, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of therapeutic proteins and antibodies that modulate the activity of G protein-coupled receptors (GPCR). The company is headquartered in Watertown, Massachusetts and currently employs 60 full-time employees. The company went IPO on 2018-06-21. The firm is focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs). Leveraging its technology platform called GEODe (GPCRs Engineered for Optimal Discovery), the Company is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery and harness the human body to modify the course of disease. The Company’s lead asset, TX000045 (TX45), is a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone relaxin. TX45 is being evaluated in Phase Ia/Ib clinical trials as a potential treatment for Group 2 Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (HFpEF). TX002100 (TX2100) is its second development candidate for the treatment of Hereditary Hemorrhagic Telangiectasia (HHT).
Company Info
IPO: 2018-06-21
TECTONIC THERAPEUTIC INC
490 Arsenal Way, Suite 210
Watertown MASSACHUSETTS US
Employees: 60
Phone: 13396663320
TECTONIC THERAPEUTIC INC / TECX FAQ
What does TECX do?
Tectonic Therapeutic, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of therapeutic proteins and antibodies that modulate the activity of G protein-coupled receptors (GPCR). The company is headquartered in Watertown, Massachusetts and currently employs 60 full-time employees. The company went IPO on 2018-06-21. The firm is focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs). Leveraging its technology platform called GEODe (GPCRs Engineered for Optimal Discovery), the Company is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery and harness the human body to modify the course of disease. The Company’s lead asset, TX000045 (TX45), is a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone relaxin. TX45 is being evaluated in Phase Ia/Ib clinical trials as a potential treatment for Group 2 Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (HFpEF). TX002100 (TX2100) is its second development candidate for the treatment of Hereditary Hemorrhagic Telangiectasia (HHT).
Can you provide the latest stock price for TECTONIC THERAPEUTIC INC?
The current stock price of TECX is 30.72 USD. The price decreased by -1.19% in the last trading session.
What is the dividend status of TECTONIC THERAPEUTIC INC?
TECX does not pay a dividend.
What is the ChartMill technical and fundamental rating of TECX stock?
TECX has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How is the valuation of TECTONIC THERAPEUTIC INC (TECX) based on its PE ratio?
TECTONIC THERAPEUTIC INC (TECX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.05).
Should I buy TECX stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on TECX.